Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved vepdegestrant on 1 May for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
The indication applies after disease progression following at least one line of endocrine therapy and requires detection of the ESR1 mutation by an FDA-authorized test.
Vepdegestrant is described by FDA as a heterobifunctional protein degrader, placing the approval within a broader shift toward molecularly defined cancer treatment.
Sourcing note: Indication language, biomarker requirement and drug class are from FDA. This article does not provide treatment advice.
Why It Matters
Breast-cancer treatment is becoming more conditional on molecular signals. The ESR1 requirement shows how approvals increasingly pair a drug with a defined diagnostic pathway.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAVepdegestrantBreast CancerESR1Oncology